Vanda Pharmaceuticals (Vanda Pharmaceuticals) Operating Cash Flow per Share : $0.22 (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Operating Cash Flow per Share?

Vanda Pharmaceuticals's operating cash flow per share for the three months ended in Dec. 2023 was $-0.07. Vanda Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.22.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vanda Pharmaceuticals was -60.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -38.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Vanda Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

VNDA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -377.4 Med: 1.9 Max: 72.9
Current: -38.1

During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.90% per year. The lowest was -377.40% per year. And the median was 1.90% per year.

VNDA's 3-Year OCF Growth Rate is ranked worse than
84.7% of 1242 companies
in the Biotechnology industry
Industry Median: 3.75 vs VNDA: -38.10

Vanda Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Vanda Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Operating Cash Flow per Share Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.84

0.94

1.13

0.56

0.22

Vanda Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.16	0.55	-0.23	-0.04	-0.07

Competitive Comparison of Vanda Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Vanda Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanda Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Vanda Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Vanda Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	12.801	/	57.558
	=	0.22

Vanda Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-3.732	/	57.695
	=	-0.06

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22

Vanda Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

VM4:Germany VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Executives

Joakim Wijkstrom	officer: SVP, Chief Marketing Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran	officer: VP, Acting CFO & Treasurer	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams	officer: SVP & General Counsel	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos	director, officer: Chief Executive Officer	9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks	officer: SVP, Business Development	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins	director	1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones	officer: Chief Corp. Affairs Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos	director	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan	director	20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly	officer: SVP, CFO, Treasurer & Secretar	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi	officer: SVP, General Manager Europe	2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341